Stop Children's Cancer Inc

What it reported doing in 2025

Since its inception in 1981, stop children's cancer has raised over $7 million, including the bonnie's legacy endowment fund, which has approximately $1 million in perpetuity. In addition, as a result of these donations, well in excess of $20 million in national cancer institute/national institute of health (nih) grants and other awards have been received. Stop children's cancer / bonnie r. Freeman clinical trial fund: this fund continues to support the program infrastructure, including the director's position, who has led our efforts to grow pediatric cancer trials. Over the 15 years that this fund has been in place, more than 1,500 clinical trials have been conducted. Stop children's cancer / kimberly h. Flaitz research grant: this fund has been focused on supporting research on ewing's sarcoma. The team, led by dr. Elias sayour, has developed fusion-targeted mrna vaccine constructs that can now be used to adapt for ews-fl1 targeted intervention in ewing's sarcoma. The team is continuing to develop vaccines targeting a specific mutation found in ewing's sarcoma but not in normal cells, with the hope of opening a trial within the next 4 years. Lyrics for life / stop children's cancer jeffrey a. Block research grant: this funding supported dr. Paul castillo, who is working on developing novel immunotherapies to treat refractory cancers, especially t-cell leukemias and t-cell lymphomas. Given the striking results of a combinational approach using car t cells and rna nanoparticle-based vaccines, he continues to use this approach, which was reported in 2021. He has shown promising data using this immunotherapeutic combinational approach for acute myeloid leukemia, metastatic osteosarcoma, and metastatic melanoma. The promise of this approach is that it retains anticancer efficacy across a wide range of cancers.

Financial Efficiency

• Mission deployment rate: 73%; rating input score 73
• Program expense ratio: 93.2%; rating input score 93
• Fundraising efficiency: $89.07 raised per $1 spent on fundraising; rating input score 83; 83rd percentile among comparable filings

Transparency & Controls

• Consistency checks: 100%; rating input score 100; 63rd percentile among comparable filings
• Pay-setting controls: Limited
• Foreign activity oversight: Limited
• Grant itemization coverage: 100%; rating input score 100; 78th percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 100%; rating input score 100; 64th percentile among comparable filings
• Governance controls: 4 of 7 controls in place; rating input score 57
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: NotApplicable
  • Other executive compensation review process: NotApplicable
  • Form 990 shared with the board: Fail
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Missing
  • Independent financial-statement audit: Fail

Sustainability

• Operating margin: 26.5%; rating input score 79; 79th percentile among comparable filings
• Total-asset coverage ratio: 3.96; rating input score 80; 80th percentile among comparable filings
• Liabilities to assets ratio: 0; rating input score 73; 73rd percentile among comparable filings
• Officer compensation ratio: 0%; rating input score 78; 78th percentile among comparable filings

Growth

• Program expense growth: 4.2% per year; rating input score 100; 33rd percentile among comparable filings
• Revenue growth: 5.4% per year; rating input score 100; 40th percentile among comparable filings
• Asset growth: 4.3% per year; rating input score 100; 32nd percentile among comparable filings